Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05530174
Other study ID # ProHipQ Fracture
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 1, 2022
Est. completion date July 1, 2025

Study information

Verified date December 2022
Source University Hospital Bispebjerg and Frederiksberg
Contact Armita A Abedi, MD
Phone +4551358644
Email armita.armina.abedi@regionh.dk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Aim: To compare the effect of one single dose versus multiple doses of prophylactic antibiotics administered within 24 hours, on the development of PJI after surgery in patients undergoing primary THA due to an acute fracture or sequelae of proximal femoral or acetabular fractures. The study is designed as a cross-over, cluster randomized, non-inferiority trial. All Danish orthopedic surgery departments performing primary THA with the majority being within inclusion criteria will be involved: Based on national quality databases, two-year cohorts of approximately 2,000 primary THAs due to a fracture or sequelae to a fracture, conducted at all public and private orthopedic departments in Denmark, this includes 36 sites corresponding to a total of 39 departments.


Description:

The outcome measures will be extracted from the following national databases: The Civil Registration System (CRS), The Danish Hip Arthroplasty Register (DHR), The Danish National Patient Registry (DNRP), The Hospital Acquired Infections Database (HAIBA), The Danish National Prescription Database (NPR), Statistics Denmark and Danish Agency for Labour Market and Recruitment registry (STAR). Details regarding the Arms and Interventions: The preoperative dose of antibiotic must be administered prior to surgical incision and in cases of delay with regards to planned surgical incision: Dicloxacillin/Cloxacillin: If the preoperative antibiotic dose is administered >60 minutes prior to surgical incision, the initial dose must be repeated. Cefuroxime: If the preoperative antibiotic dose is administered >90 minutes prior to surgical incision, the initial dose must be repeated. Treatment A, Single-dose practice: For patients ≥ 120 kg: One preoperative single dose of either Dicloxacillin/Cloxacillin 3g OR Cefuroxime 3g administered intravenously prior to surgical incision. In cases of cephalosporin allergy or general beta lactam allergy one preoperative single dose of Clindamycin 900mg administered intravenously, prior to surgical incision, regardless of weight. Treatment B, Multiple-dose practice: For patients ≥ 120 kg: One preoperative single dose of either Dicloxacillin/Cloxacillin 3g OR Cefuroxime 3g administered intravenously prior to surgical incision, followed by 3 postoperative doses of Dicloxacillin/Cloxacillin 2g x 3 OR cefuroxime 1.5g x 3, administered within 24 hours after the preoperative dose, corresponding to 6, 12 and 18 hours postoperatively. After the first postoperative dose, the remaining doses may be administered perorally for pragmatic reasons. Dicloxacillin p.o. 1g, 12 and 18 hours postoperatively. OR Amoxicillin and clavulanic acid p.o. 875mg/125*mg, 12 and 18 hours postoperatively. *If the center or region does not have access to amoxicillin and clavulanic acid 875/125mg a dose of 1g / 125mg (this means amoxicillin 500mg + amoxicillin and clavulanic acid 500mg/125 mg) may be administered. In cases of cephalosporin allergy or general beta lactam allergy one preoperative single dose of Clindamycin 900mg administered intravenously, prior to surgical incision, regardless of weight, followed by 2 postoperative doses corresponding to: For patients <120kg: 300mg, 8 and 16 hours postoperatively. For patients ≥ 120kg: 600mg, 8 and 16 hours postoperatively. The same doses apply in cases of transmission to peroral antibiotics. Implementation: The senior biostatistician is responsible for the randomization process of the centers. Each center will be allocated a code by the senior biostatistician responsible and reported to a central database. The randomization and allocation procedure will be known for the given year conditioning the given center. Ethics and Dissemination: This trial has been approved by the Regional Ethical Committee (VEK) (21069108) and The Danish Medicines Agency (2021091723) without imposing an obligation to notify.


Recruitment information / eligibility

Status Recruiting
Enrollment 2000
Est. completion date July 1, 2025
Est. primary completion date November 30, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - All patients receiving a primary Total Hip Arthroplasty (THA) due to an acute- or sequelae of proximal femoral or acetabular fractures Exclusion Criteria: - Patients receiving a primary THA due to bone tumor or metastasis - Patients receiving a primary THA due to osteoarthritis and all reasons according to the Danish Hip Arthroplasty Register (DHR) except conditions mentioned in the inclusion criteria

Study Design


Intervention

Other:
Antibiotic dosage practice
Patient inclusion starts day one, cross-over of departments from treatment A (single-dose) to B (multiple-dose) or vice versa after one year and end of inclusion happens after 2 years. All centers in Denmark use either Cloxacillin/Dicloxacillin, Cefuroxime or both drugs as standard prophylactic antibiotic practice for THA. In cases of cephalosporin allergy or general beta lactam allergy, the antibiotic clindamycin may be administered. In this trial, patients will be administered the standard prophylactic antibiotic practice of either single-dose (A) or multiple-doses (B) of antibiotics administered at each respective cluster that respective year. Both practices of dose administration for antibiotic prophylaxis (i.e. single- or multiple-dose) follow current standards of treatment and are based on present clinical practice guidelines.

Locations

Country Name City State
Denmark Department of Orthopedic Surgery, Aabenraa and Sønderborg, Hospital of Southern Jutland Aabenraa
Denmark Capio Private Hospital, Aalborg Aalborg
Denmark Department of Orthopedic Surgery, Aalborg, Aalborg University Hospital Aalborg
Denmark Aleris Private Hospital, Aarhus Aarhus
Denmark Deaprtment of Orthopaedic Surgery, Aarhus University Hospital Aarhus
Denmark Capio Private Hospital, Aarhus Aarhus C
Denmark Capio Private Hospital, Gildhøj Brøndby
Denmark Department of Orthopedic Surgery and Traumatology, Bispebjerg, Copenhagen University Hospital - Bispebjerg and Frederiksberg Copenhagen NV
Denmark Adeas Private Hospital, Parken Copenhagen Ø
Denmark Department of Orthopedic Surgery, Esbjerg, Hospital of South West Jutland Esbjerg
Denmark Department of Orthopedic Surgery, Farsø, Aalborg University Hospital Farsø
Denmark CPH Private Hospital Farum
Denmark Department of Orthopedic Surgery, Frederikshavn, Aalborg University Hospital Frederikshavn
Denmark Department of Orthopedic Surgery, Grindsted, Hospital of South West Jutland Grindsted
Denmark Capio Private Hospital, Hellerup and Odense Hellerup
Denmark Department of Orthopaedic Surgery, Gentofte, Copenhagen University Hospital - Herlev and Gentofte Hellerup
Denmark Department of Orthopaedic Surgery, Herlev, Copenhagen University Hospital - Herlev and Gentofte Herlev
Denmark Department of Orthopedic Surgery, Gødstrup Regional Hospital Herning
Denmark Department of Orthopedic Surgery, Hillerød, Copenhagen University Hospital - North Zealand Hillerød
Denmark Department of Orthopedic Surgery, Copenhagen University Hospital - Holbæk Holbæk
Denmark Department of Orthopedic Surgery, Horsens Regional Hospital, Denmark Horsens
Denmark Department of Orthopedic Surgery, Hvidovre, Copenhagen University Hospital - Amager and Hvidovre Hvidovre
Denmark Department of Orthopedic Surgery, Zealand University Hospital, Køge Køge
Denmark Acure Private Hospital Kongens Lyngby
Denmark Kollund Private Hospital, Kollund Kruså
Denmark Department for Planned Orthopaedic Surgery, Næstved, Copenhagen University Hospital - Næstved, Slagelse and Ringsted Næstved
Denmark Department of Orthopedic Surgery, Copenahegn University Hospital - Nykøbing F. Nykøbing Falster
Denmark Department of Orthopedic Surgery and Traumatology, Odense University Hospital and Svendborg Hospital Odense
Denmark Deparmtent of Orthopedic Surgery, Randers Regional Hospital Randers
Denmark Aleris Private Hospital, Ringsted Ringsted
Denmark Department of Surgery, Copenhagen University Hospital - Bornholm Rønne
Denmark Center for Planned Surgery, Silkeborg Regional Hospital Silkeborg
Denmark Aleris Private Hospital, Søborg Søborg
Denmark Department of Orthopedics, Lillebaelt Hospital, Vejle Vejle
Denmark Mølholm Private Hospital, Vejle Vejle
Denmark Deparmtent of Orthopedic Sugery, Viborg Regional Hospital Viborg

Sponsors (7)

Lead Sponsor Collaborator
Soren Overgaard Aarhus University Hospital, Odense University Hospital, Sygehus Lillebaelt, University Hospital Bispebjerg and Frederiksberg, University of Aarhus, University of Copenhagen

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Other Incremental cost-effectiveness The incremental cost-effectiveness will be calculated based on the costs per patient in the two antibiotic practices. Costs related to antibiotic prophylaxis, hospital admissions and readmissions, hospital outpatient visits, visits to General practitioner and costs related to sick leave from work will be included.
Data will be collected from:
The Danish National Patient Registry (DNPR)
The Civil Registration System (CRS)
The Danish Agency for Labor Market and Recruitment registry STAR
Within 90 days from index surgery
Other Rate of revision after THA Revision surgery is defined as a new surgical intervention the first time after the primary intervention including debridement alone or in combination with complete or partial removal or exchange of the implant. Revision due to any cause including PJI and aseptic loosening are included.
Revision risk is recorded from DHR and DNPR.
Within 1 year from index surgery
Other Mortality rate after index surgery 1-year mortality rate is defined by date of death due to any cause after index surgery. Data is collected from The Civil Registration System (CRS). Within 1 year from index surgery
Other Incidence of Superficial incisional Surgical Site Infection To be defined Within 90 days from index surgery
Primary Incidence of Prosthetic joint infections (PJI) The definition of PJI is based on revision surgery. Revision surgery is defined as a new surgical intervention the first time after the primary intervention including debridement alone or in combination with complete or partial removal or exchange of the implant.
The definition of PJI is based on revision surgery. Revision surgery is defined as a new surgical intervention the first time after the primary intervention including debridement alone or in combination with complete or partial removal or exchange of the implant.
Two or more intraoperative deep-tissue samples of phenotypically indistinguishable bacteria isolated from at least 3 deep-tissue samples
One or more positive intraoperative samples from a closed fluid aspirate AND a biopsy (fluid AND tissue) of phenotypically indistinguishable bacteria isolated
A PJI when an indication of deep infection is reported to The Danish Hip Arthroplasty Registry (DHR) by the surgeon upon revision surgery
Within 90 days from index surgery
Secondary Number of patients with one or more Serious Adverse Events (SAEs) SAEs are defined according to the ICH-GCP guidelines. SAE refers to an event involving a significant risk of death or disability of the patient (or their offspring), including, but not limited to, an event that:
results in death
is life-threatening - in the investigator's opinion the patient was in immediate risk of death from the adverse event when it appeared
requires hospitalization or prolongs existing hospitalization
results in permanent or significant disability
is a congenital anomaly SAEs are recorded from The Danish National Patient Registry (DNPR).
Within 90 days from index surgery
Secondary Incidence of Potential PJI referred to as PJI-likely PJI-likely is defined as at least one of the two criteria:
One single intraoperatively obtained positive culture (aspiration fluid OR tissue biopsy) regardless of microorganism
One single positive culture obtained from aspiration of synovial fluid regardless of microorganism AND any antibiotic prescriptions (ATC category J01) redeemed
Within 90 days from index surgery
Secondary Length of hospital stay (LOS) LOS defined as number of postoperative overnight stays, including transferals to other departments and hospitals. Data on LOS is acquired from DNPR. Within 90 days from index surgery
Secondary Incidence of Thromboembolic complications incl VTE, MI, AF, stroke VTE is defined a priori as both deep venous thromboembolisms confirmed by compression ultrasound and pulmonary embolism confirmed by spiral computed tomography (CT), ventilation-perfusion scintigraphy or pathological removal of an embolus and based on the following diagnostic ICD10 codes: I26, I80.1-I80.9, I82.1-I82.9, or T81.7B-D. Data will be extracted from DNPR. Within 90 days from index surgery
Secondary Hospital-treated infections (excluding Surgical Site infections) Any Hospital-treated infection is defined as any first-time hospital admission with a primary or secondary infection diagnosis after discharge from index THA surgery. Hospital-treated infections are identified from DNPR.
The list of infections includes chronic and more rare infections, to detect possible flare-up in any possible ongoing infections.
The list will exclude urinary tract infections (UTI) due to a high risk of different registration praxis registration for UTI among hospitals in Denmark.
Within 90 days from index surgery
Secondary Proportion of patients with at least one dispensing for antibiotic Community-based antibiotic use (any community-treated infection or antibiotic use after discharge) is defined as at least one dispensing after discharge from index THA surgery within 90 days for narrow- and broad-spectrum antibiotics based on the Anatomical Therapeutic Chemical classification (ATC) codes. All antibiotics in Denmark require prescriptions from a physician. The Danish National Health Service Prescription Database has registered all reimbursed prescriptions from all community pharmacies since 2004. Medications are coded according to the following ATC codes: J01CE, J01CF, J01DB, J01DC, J01DD, J01DE, J01DH, J01DI, J01CR, J01CA, J01F. J01E, J01MA ,J01AA Within 90 days from index surgery
Secondary Proportion of patients with a least one dispensing for opioids Prescriptions redeemed is defined as at least 1 prescription dispensing of any opioid. Prescriptions of analgesics will be identified through The Danish National Prescription Registry. The registry contains information on all prescriptions redeemed by Danish residents in community pharmacies since 1995 (excluding hospital dispensaries). Information on Anatomical Classification System (ATC) codes and dispensation date will be applied to identify opioids. Following ATC codes (including all sub codes) are included: N01AH (opioid anesthetics), N02A (opioids), N07BC02 (methadone), and R05DA04 (codeine). Duration of treatment will be calculated based on no. of packages and volume. Within 90 days from index surgery
Secondary Proportion of patients with dispensing for acetaminophen or non-steroid anti-inflammatory drug Prescription redeemed is defined as at least 1 prescription dispensing of any acetaminophen or NSAID within 90 days after index THA surgery. Prescriptions of analgesics are identified using the Danish National Prescription Registry. Information on Anatomical Classification System (ATC) codes and dispensation date will be applied to identify acetaminophen and NSAID. Following ATC codes (including all sub codes) are included M01A (NSAIDs). Duration of treatment will be calculated based on no. of packages and volume. Within 90 days from index surgery
See also
  Status Clinical Trial Phase
Terminated NCT02818894 - Spinal Anesthesia in Total Hip Arthroplasty Phase 4
Completed NCT02242201 - Total Hip Arthroplasty (THA) Lumbar Plexus Verses Periarticular Phase 4
Completed NCT02414542 - Minima Clinical Study
Completed NCT01817010 - Strength and Function Following Total Hip Arthroplasty N/A
Completed NCT01443975 - Clinical Evaluation on the Use of the X-pander Device N/A
Recruiting NCT05530551 - Effect of Single vs Multiple Prophylactic Antibiotic Doses on PJI Following Primary THA in Patients With OA N/A
Recruiting NCT06141928 - Comparison of Three Different Surgical Approaches on the Functional Outcome After Total Hip Arthroplasty N/A
Recruiting NCT05054192 - Reliability and Validity of Modified Four Square Step Test
Recruiting NCT04492462 - The Impact of Two Different Physical Therapy Programs in the Rehabilitation of Patients Undergoing Anterior Approach Hip Replacement Surgery N/A
Withdrawn NCT02926651 - Single Versus Multi-Dose Oral Tranexamic Acid in Patients at High Risk for Blood Transfusion After Total Joint Arthroplasty Phase 4
Completed NCT02308813 - Predictability of the Ability to Perform an Emergency Stop With Disorders of the Hip N/A
Recruiting NCT02032017 - Percutaneous Assisted Approach for Total Hip Replacement and it's Effect on Functional Rehabilitation. N/A
Recruiting NCT01312077 - The Analgesic Efficacy of Periarticular Infiltration of Local Anaesthetic for Total Hip Replacement Phase 4
Withdrawn NCT01380665 - Prevena™ Incision Management System Over Primarily Closed Hip and Knee Incisions in Patients Immediately Post Total Hip and Knee Arthroplasty Phase 4
Recruiting NCT05893563 - Corail Stability at 5-Years Post-Total Hip Arthroplasty
Recruiting NCT06088069 - Effect of Virtual Reality on Perioperative Anxiety, Stress and Pain in Total Hip Arthroplasty N/A
Active, not recruiting NCT03210844 - The Clinical Outcomes After Direct Anterior Approach and Microposterior Approach for Total Hip Arthroplasty N/A
Recruiting NCT04801680 - Mpact 3D Metal Cup PMS
Terminated NCT02006251 - Real-Time Instrument for Acetabular Shell Positioning
Completed NCT01525667 - Safety and Efficacy of IM Injections of PLX-PAD for the Regeneration of Injured Gluteal Musculature After Total Hip Arthroplasty Phase 1/Phase 2